Abstract
A short-course regimen of zidovudine plus lamivudine starting from 34 weeks' gestation in pregnant women to prevent mother-to-child HIV infection, and discontinued after delivery, was evaluated for the development of resistance at 6 weeks postpartum. No resistant mutation was found in 32 women. One of the three infected infants carried the M184V and K219Q mutations.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-HIV Agents / administration & dosage*
-
Drug Resistance, Viral / genetics*
-
Drug Therapy, Combination
-
Female
-
HIV Infections / drug therapy*
-
HIV Infections / genetics
-
Humans
-
Infectious Disease Transmission, Vertical / prevention & control*
-
Lamivudine / administration & dosage*
-
Mutation / genetics*
-
Pregnancy
-
Pregnancy Complications, Infectious / prevention & control*
-
Zidovudine / administration & dosage*
Substances
-
Anti-HIV Agents
-
Lamivudine
-
Zidovudine